

1 Revised version 2018-03-13

2 **Infection and Immunity**

3

4 MINIREVIEW

5 **Are Sphingolipids and Serine Dipeptide Lipids underestimated Virulence**

6 **Factors of *Porphyromonas gingivalis*?**

7 Ingar Olsen,^a and Frank C. Nichols^{b,*}

8 ^aDepartment of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway

9 ^b Department of Oral Health and Diagnostic Sciences of the University of Connecticut School of
10 Dental Medicine, Farmington, CT, USA

11 ^{*} Corresponding author.

12 Address for correspondence to nichols@uchc.edu

13 Department of Oral Health and Diagnostic Sciences, MC 1710

14 University of Connecticut School of Dental Medicine

15 263 Farmington Avenue

16 Farmington, CT 06030 USA

17

18

19

20

21 **ABSTRACT**

22

23 The keystone periodontal pathogen *Porphyromonas gingivalis* produces phosphorylated
24 dihydroceramide lipids (sphingolipids) such as phosphoethanolamine dihydroceramide (PE
25 DHC) and phosphoglycerol dihydroceramide (PG DHC) lipids. Phosphorylated DHCs (PDHCs)
26 from *P. gingivalis* can affect a number of mammalian cellular functions such as potentiation of
27 prostaglandin secretion from gingival fibroblasts, promotion of RANKL-induced
28 osteoclastogenesis, promotion of apoptosis and enhancement of autoimmunity. In *P. gingivalis*,
29 these lipids affect anchoring of surface polysaccharides, resistance to oxidative stress and
30 presentation of surface polysaccharides (anionic polysaccharides and K-antigen capsule). In
31 addition to phosphorylated dihydroceramide lipids, serine dipeptide lipids of *P. gingivalis* are
32 implicated in alveolar bone loss in chronic periodontitis through interference with osteoblast
33 differentiation and function, and promotion of osteoclast activity. As a prerequisite for
34 designation as bacterial virulence factors, bacterial sphingolipids and serine dipeptide lipids are
35 recovered in gingival/periodontal tissues, tooth calculus, human blood, vascular tissues and brain.
36 In addition to *P. gingivalis*, other bacteria of the genera *Bacteroides*, *Parabacteroides*,
37 *Porphyromonas*, *Tannerella* and *Prevotella* produce sphingolipids and serine dipeptide lipids.
38 The contribution of PDHCs and serine dipeptide lipids to the pathogenesis of periodontal and
39 extraoral diseases may be an underappreciated area for microbial-host interaction and should be
40 more intensively investigated.

41

42 **KEYWORDS:** *P. gingivalis*, virulence factors, sphingolipids, ceramides, periodontitis, extraoral
43 diseases

44

45

46 INTRODUCTION

47
48
49 Sphingolipids, as amphipathic molecules, demonstrate both hydrophobic and hydrophilic
50 constituents and, as such, have long been considered little more than structural lipid components
51 of eukaryotic cell membranes. More recent studies, however, have shown that mammalian
52 sphingolipids such as ceramide (the simplest sphingolipid), sphingosine and sphingosine-1-
53 phosphate lipids, are central to a number of important biological processes. Mammalian
54 sphingolipids are known to make complexes with proteins and other cell membrane lipids, often
55 sterols, to form so-called lipid rafts (1, 2). Lipid rafts are fluctuating nanoscale collections of
56 sphingolipid, cholesterol and proteins in cell membranes, constituting platforms that operate in
57 membrane signaling and trafficking. Of note, most bacteria of the Bacteroidetes phylum and a
58 few bacteria of the Chlorobi phylum (3) produce sphingolipids but only members of the
59 Bacteroidetes phylum are reported to produce novel serine dipeptide lipids (4-7). These lipid
60 classes demonstrate amphipathic characteristics and possess important biological properties.
61 When members of the Bacteroidetes phylum, particularly oral Bacteroidetes, contact human cells,
62 bacterial sphingolipids and serine lipids may incorporate into the eukaryotic cell membranes
63 thereby potentially affecting cell function. As an example, lipid raft components are used by the
64 periodontal pathogen *Porphyromonas gingivalis* (8), for entry into host epithelial cells (9, 10).

65 Chronic periodontitis is manifested as progressive loss of periodontal attachment and alveolar
66 bone, leading to pathological pocket formation around the teeth. If left untreated, it can lead to
67 loss of teeth. Chronic periodontitis affects approximately 65 million (47 %) US adults of 30 years
68 and older (11). Chronic periodontitis has also been associated with extraoral diseases such as
69 cardiovascular diseases, diabetes, preterm birth, Alzheimer's disease, rheumatoid arthritis and
70 pancreatic cancer (12-14). The keystone periodontal pathogen *P. gingivalis* produces many
71 virulence factors of which the major classes include lipopolysaccharide (LPS), a polysaccharide-
72 rich capsule, gingipains, fimbriae and peptidyl-arginine deiminase. *P. gingivalis* LPS is
73 considered to be important in bone destruction in periodontitis. However, previous reports have
74 shown that LPS of *P. gingivalis* is present only in minor amounts in diseased periodontal tissues
75 from humans (15, 16). In contrast to LPS, *P. gingivalis* dihydroceramides (DHCs) (17, 18) and

76 serine dipeptide lipids (19) are exposed to diseased gingival tissues at levels capable of inducing
77 an inflammatory response (20).

78 Within the diseased periodontal crevice (pocket), *P. gingivalis* is known to directly contact and
79 attach to sulcular epithelial cells (21) (FIGURE 1), and co-culture of *P. gingivalis* with epithelial
80 cells reveals an ultrastructural thickening of the merged membranes as *P. gingivalis* is
81 internalized (22). This cell membrane contact could deliver bacterial lipids directly to the cell
82 membranes of host epithelial cells. Another mechanism for bacterial lipid entry into cells is
83 demonstrated by the uptake of total lipids of *P. gingivalis* into human gingival fibroblasts when
84 cells are exposed to lipid films in culture (20). Therefore, *P. gingivalis* lipids are likely
85 transferred to cells of gingival tissues either by direct contact with bacteria or by chemical
86 diffusion from lipid contaminated surfaces of diseased teeth. Either process can lead to
87 deposition of bacterial lipids into eukaryotic cell membranes, thereby exposing cells, including
88 lipid rafts, to elevated levels of non-mammalian sphingolipids and serine dipeptide lipids. In
89 contrast to periodontal Bacteroidetes, gastrointestinal *Bacteroides* are recovered primarily in the
90 colon (3) but little is known about breakdown of these bacterial sphingolipids in the colon or their
91 transport within this organ.

92 *P. gingivalis* produces several classes of phosphorylated dihydroceramides (PDHCs) as well as
93 other novel complex lipids (see TABLE 1, FIGURE 2 and 3) including serine dipeptide lipids.
94 The first to be characterized were the sphingolipids which are quite similar but not identical to
95 mammalian sphingolipids. PDHCs can be detected in, quantitated and distinguished from
96 eukaryotic sphingolipids using multiple reaction monitoring (MRM)-mass spectrometry (MS)
97 (23). The sphingoid bases in *P. gingivalis* DHC lipids comprise saturated aliphatic chains of 17,
98 18 or 19 carbons with *isobran*ching of the odd numbered carbon chains (see FIGURE 2) (17, 18).
99 The sphingoid base is designated sphinganine (dihydrosphingosine) or dihydroceramide (DHC)
100 when amide-linked to a fatty acid chain, which in *P. gingivalis* sphingolipids is usually 3-OH
101 *isobran*ched C_{17:0} (see FIGURE 2) (18). From *P. gingivalis* lipid extracts, three major DHC
102 species have been recognized: the free DHC, phosphoethanolamine DHC (PE DHC) and
103 phosphoglycerol DHC (PG DHC) lipids (17, 18). The free DHC lipids are presumed to serve as
104 precursor core structures for the synthesis of PE DHC and PG DHC lipids (see FIGURE 2). The
105 *isobran*ched aliphatic chains of phosphoglycerol dihydroceramides and

106 phosphatidylethanolamines (PEA) of *P. gingivalis* (see [FIGURE 2](#)) are thought to be partially
107 responsible for the bioactivity of these lipids (24). PG DHC can be further modified with the
108 addition of *isobranched* C_{15:0} to the 3-OH group of the dihydroceramide core fatty acid chain
109 (18). This lipid was later termed substituted (sub) PG DHC but in some prior reports, the term PG
110 DHC was used instead of sub PG DHC. However, if PG DHC lipids are not substituted with
111 *iso*C_{15:0} or other fatty acids, this class was specifically designated as unsub PG DHC lipids in
112 previous reports (see [FIGURE 2](#)).

113 Contrasted with the structures of PDHC lipids are the serine dipeptide lipids of *P. gingivalis*,
114 including Lipid 654 and Lipid 430 ([FIGURE 3](#)). Lipid 654 of *P. gingivalis*, which is the
115 dominant serine dipeptide lipid class of *P. gingivalis*, was first described in *Fusobacterium*
116 *meningosepticum* and was termed flavolipin (7). Flavolipin was originally reported to be a Toll-
117 like receptor 4 ligand (4) but recent work has shown that Lipid 654 is a TLR2 ligand rather than a
118 TLR4 ligand (19, 25). Toll-like receptors are known to recognize exogenous ligands and are
119 reported to function within lipid rafts (26). Just as with *P. gingivalis* sphingolipids, serine
120 dipeptide lipids are recovered in diseased periodontal tissues (19) as well as blood (27) and artery
121 walls of humans (6). Of physiological importance is that the mammalian enzyme phospholipase
122 A2 (PLA2), typically expressed in chronic inflammatory reactions, hydrolyzed Lipid 654 of *P.*
123 *gingivalis* to another serine lipid class called Lipid 430 (5, 6). Just as with Lipid 654, Lipid 430
124 also activated human embryonic kidney cells transfected with human TLR2 and also increased
125 serum CCL2 (MCP-1) levels in wild type mice but not TLR2 knockout mice (19). However,
126 mouse osteoblast function and differentiation were markedly inhibited by Lipid 430 regardless of
127 TLR2 status (25). In this brief review, focus is directed toward sphingolipids and serine
128 dipeptide lipids of *P. gingivalis*, and their potential roles as virulence factors, particularly as they
129 relate to bone loss in chronic periodontitis. Sphingolipids in both bacteria and fungi have
130 previously been reviewed (28).

131

132 **POTENTIATION OF PROSTAGLANDIN SECRETION FROM GINGIVAL** 133 **FIBROBLASTS**

134 It is reasonable to suspect that penetration of bacterial lipids into gingival tissues combined with
135 chronic inflammation can promote destructive periodontitis. *P. gingivalis* total lipids (20), PG
136 DHC lipids (18) and phosphatidylethanolamine lipids (PEA) (24) promoted interleukin-1 β (IL-
137 1 β)-mediated secretion of inflammatory mediators (prostaglandin E₂ (PGE₂) and 6-keto
138 prostaglandin F_{2 α}) from human gingival fibroblasts and changed their cellular morphology in
139 culture (18, 24). The potentiation of PGE₂ synthesis and secretion from fibroblasts, possibly
140 mediated through TLR2, could be an important mechanism for *P. gingivalis* to promote
141 inflammatory reactions and change host responses including osteoclast mediated bone resorption,
142 thereby promoting tissue breakdown in periodontal disease.

143

144 **PROMOTION OF RANKL-INDUCED OSTEOCLASTOGENESIS**

145 A possible effect of PG DHC on alveolar bone destruction, which is an essential feature of
146 periodontitis, has been reported recently. PG DHC lipids were found to promote receptor
147 activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis by interacting
148 with non-muscle myosin IIA (Myh9) (29). The latter is an osteoclast cell fusion regulatory cell
149 protein localized to the cytoplasm of host cells. Myh9 elicited a signal that made Ras-related C3
150 botulinum toxin substrate 1 (Rac1) upregulate the expression of dendritic cell-specific
151 transmembrane protein (DC-STAMP). The latter is known as a key osteoclast fusogen that is
152 responsible for the cell fusion process during osteoclastogenesis. Noteworthy, the process
153 depended on Rac1/DC-STAMP and not on TLR2/TLR4 engagement. Thus, instead of binding to
154 TLR2/4 expressed on the cell surface, PG DHC interacted with a cytoskeletal protein that is
155 localized to the cytoplasm. In addition, non-muscle myosin IIA (Myh9) produced a cell signal
156 that involved Rac1 to upregulate the expression of DC-STAMP. This key osteoclast fusogen is
157 responsible for the process of cell fusion during osteoclastogenesis. Further, the study clearly
158 showed that PG DHC could penetrate cell membranes of osteoclast precursors and enter the
159 nuclei. This brought significant new insight into the process of macrophage fusion required for
160 osteoclast formation and promotion of osteoclast-induced bone breakdown associated with the
161 development of chronic periodontitis.

162

163 **PDHC AND SERINE DIPEPTIDE LIPID INTERFERENCE WITH**
164 **OSTEOBLAST DIFFERENTIATION AND OTHER CELLULAR EFFECTS**

165

166 Total lipids from *P. gingivalis* and PE DHC and PG DHC lipids prepared free of lipid A were
167 studied for their effects on primary calvarial osteoblast cultures from mice (30). This
168 investigation revealed that osteoblast differentiation and fluorescent transgene expression for
169 calvarial osteoblast differentiation (the transgene for the rat type I collagen promoter fragment
170 pOBCol2.3GP) (31), were inhibited in a concentration-dependent manner. Osteoblast
171 proliferation, viability or apoptosis were not markedly affected. Simultaneously, common
172 osteoblast differentiation genes were downregulated (*Runx2*, *ALP*, *OC*, *BSP*, *OPG* and *DMP-1*)
173 whereas RANKL, tumor necrosis factor alpha and *MMP-3* genes were upregulated. Mineral
174 nodule formation *in vitro* was prevented. Total lipids and PE DHC and PG DHC lipid fractions of
175 *P. gingivalis* also inhibited calvarial osteoblast gene expression and function *in vivo*. These lipid
176 preparations inhibited osteoblasts through TLR2 engagement, which agrees with observations on
177 alveolar bone loss in animals infected orally with *P. gingivalis* (32-34). They could therefore act
178 as a microbial virulence factor in periodontitis by inhibiting osteoblast function and gene
179 expression. More recent work isolated a serine dipeptide lipid fraction from *P. gingivalis* lipids
180 using HPLC fractionation with an acidic solvent together with improved HPLC equipment
181 capable of considerably improved chromatographic resolution. Though serine dipeptide lipids (6,
182 25) are minor lipid constituents of the total lipids of *P. gingivalis*, this approach allowed the
183 purification of serine dipeptide lipids essentially free of contaminating phosphorylated
184 dihydroceramides and other complex lipids. The serine dipeptide lipid class, Lipid 654, has since
185 been shown to account for the TLR2-dependent inhibition of osteoblast differentiation and
186 function (25). It was reported that PE DHC lipids of *P. gingivalis* also increased secretion of IL-
187 6 from dendritic cells *in vitro* (35) and this effect was mediated through engagement of TLR2. It
188 was later determined using improved HPLC equipment that trace amounts of Lipid 654
189 contaminating the PE DHC lipid preparation were likely accounting for the TLR2-mediated
190 effect on dendritic cells (see [FIGURE 3](#)) (19). The serine dipeptide lipids may also promote
191 extraoral inflammatory diseases, e.g., cardiovascular diseases (6). This idea is supported by the
192 fact that dihydroceramide and serine dipeptide lipids are not only found in gingival tissues but

193 also in human blood, vascular tissue and brain (23). Recently, it was suggested that commensal
194 Bacteroidetes, to which *P. gingivalis* belongs, that reside in the oral cavity and gut contribute to
195 the pathogenesis of TLR2-dependent atherosclerosis through deposition and metabolism of serine
196 dipeptide lipids in artery walls (6). In addition to *P. gingivalis*, the common dental pulpal
197 pathogen *P. endodontalis*, produces the Lipid 654 class (36). The Lipid 654 preparations isolated
198 from both *Porphyromonas* species were shown to promote osteoclast formation from RAW
199 264.7 cells (36) indicating that in addition to sub PG DHC lipids, osteoclast activation is
200 promoted by serine dipeptide lipids and that bacterial source of Lipid 654 is probably not a
201 critical issue.

202 Interestingly, phosphorylated dihydroceramide and serine dipeptide lipids have been reported to
203 contaminate free lipid A isolated from *P. gingivalis* LPS (37) and may be responsible, at least to
204 some extent for the TLR2-mediated effects of *P. gingivalis* LPS on osteoblasts (38). Regardless,
205 the PG DHC and serine dipeptide lipids mediate important effects on bone cells and therefore
206 should be regarded as virulence factors.

207

208 **PROMOTION OF APOPTOSIS**

209 Although *P. gingivalis* dihydroceramides promote inflammatory secretory reactions in
210 fibroblasts, little is known about their effects on vascular cells. Zhalten et al. (39) studied the
211 effects of extracted and purified *P. gingivalis* lipids on endothelial cells from the human
212 umbilical vein. The PG DHC (sub PG DHC) lipid fraction but not the PE DHC lipid fraction of
213 *P. gingivalis* initiated endothelial cell apoptosis *in vitro*, but not necrosis. PG DHC activated
214 caspase 3, 6 and 9. Inhibition of these caspases significantly reduced PG DHC-mediated
215 apoptosis in endothelial cells. Sub PG DHC also induced release of apoptosis-inducing factor.
216 Pre-incubation of cells with the reactive oxygen species (ROS) scavenger N-acetylcysteine
217 reduced *P. gingivalis*-induced endothelial apoptosis. Apoptosis was stimulated by exogenous
218 synthetic sphingosines similar to endogenous mammalian ceramides formed in endothelial and
219 other cells (39). In addition, *P. gingivalis*-derived lipids were able to induce apparent apoptosis in
220 gingival fibroblasts (18) similar to apoptosis later reported in gingival fibroblasts when co-
221 cultured with *P. gingivalis* (40) and in chondrocytes with exposure to *P. gingivalis* itself (41, 42).
222 It was proposed that lipids from *P. gingivalis* might induce apoptosis in joints even in the absence

223 of live *P. gingivalis* (42), which is noteworthy. The authors also suggested that *P. gingivalis*
224 lipids could interfere with and impair the repair process in cartilage, thereby linking *P. gingivalis*
225 to rheumatoid arthritis (42-45).

226

227 **EXPRESSION AND ANCHORING OF SURFACE POLYSACCHARIDES**

228 Moye et al. (46) recently reported that deletion of the PG1780 gene in *P. gingivalis* strain W83
229 rendered this organism unable to produce dihydroceramide lipids. The PG1780 gene encodes for
230 the putative serine palmitoyltransferase enzyme of *P. gingivalis*. Serine palmitoyltransferase is
231 the enzyme responsible for the first step in the synthesis of long chain base precursors of
232 sphingolipids. Moye et al. (46) showed that the Δ PG1780 mutant is devoid of dihydroceramide
233 lipids whereas dihydroceramide synthesis was restored in the complemented mutant strain
234 (Δ PG1780 pTCOW-1780). In addition, electron micrographic evaluation of the Δ PG1780
235 mutant suggested that surface glycans were diminished. Further evaluation demonstrated that the
236 Δ PG1780 mutant expressed low levels of K-antigen but showed increased expression of anionic
237 polysaccharide relative to the W83 parent strain. Of note, the K1 capsule null strain (Δ PG0106)
238 showed very low expression of both K antigen and anionic polysaccharide when compared with
239 the Δ PG1780 mutant or parent strain. These results demonstrate that sphingolipid synthesis in *P.*
240 *gingivalis* is associated with the expression of specific cell surface polysaccharides although the
241 exact role of sphingolipids in this process remains to be determined. Moye et al. (46) also
242 demonstrated that lack of sphingolipid synthesis by *P. gingivalis* decreased the expression of cell-
243 associated arginine (Arg) and lysine (Lys) gingipains (46), the “trypsin like” proteases expressed
244 by this organism. Bainbridge et al. (48) found that deletion of a 77bpIR element at the 5'end of
245 the K-antigen capsule synthesis locus of *P. gingivalis* changed the presentation of capsule, O-
246 LPS, and A-LPS, and reduced cell-associated Arg- and Lys-gingipain activity. This evidence
247 suggests that sphingolipid synthesis may alter cell surface gingipain expression indirectly though
248 reduced K antigen expression. Finally, the lipid moiety responsible for covalently anchoring
249 capsular polysaccharides to the outer membrane has been identified in only a few bacterial
250 species (47) and includes the direct covalent attachment of capsular polysaccharides to a lyso-
251 phosphatidylglycerol motif as reported by Willis et al. (47). It is unknown whether capsular

252 polysaccharides are anchored to sphingolipids in *P. gingivalis* cell membranes. Future research is
253 expected to clarify this possibility.

254

255

256 **RESISTANCE TO OXIDATIVE STRESS**

257 Moye et al. (46) reported that the Δ PG1780 sphingolipid-deficient strain of *P. gingivalis* was
258 more sensitive to oxidative stress after exposure to oxygen even for very short intervals. When
259 the parental strain and the mutant Δ PG1780 were cultured to early exponential phase and the
260 cultures were treated with 150-250 μ M hydrogen peroxide or water as control, the parental strain
261 survived the addition of all concentrations of hydrogen peroxide. The mutant cultures treated
262 with 200 or 250 μ M H₂O₂ were quickly killed and did not recover after 30 h. Cultures of the
263 mutant strain exposed to the lowest concentration of hydrogen peroxide (150 μ M), decreased
264 initially in density, but recovered by the end of the experiment. This demonstrated that the
265 Δ PG1780 mutant was much more sensitive to hydrogen peroxide than the parental strain.
266 Accordingly, sphingolipids seem to play an important role in the resistance of *P. gingivalis* to
267 oxidative stress and therefore to the survival of this bacterium. A report by An et al. (49)
268 indicated that sphingolipids are important in *Bacteroides fragilis* protection from oxidative stress.
269 However, a previous report demonstrated that *B. fragilis* does not produce PG DHC lipids (23),
270 suggesting that PE DHC sphingolipids may be important in protection of *B. fragilis* from
271 oxidative stress. Also, other factors can participate in the resistance of *P. gingivalis* to oxidative
272 damage such as antioxidant enzymes, DNA binding protein (Dps), the hemin layer, enzymatic
273 removal of deleterious products caused by ROS and response regulators (for a review see (50)).

274

275 **ENHANCEMENT OF AUTOIMMUNITY**

276 Phosphorylated dihydroceramides are derived from Bacteroidetes bacteria found in multiple sites
277 in humans such as the oral cavity, the gastro-intestinal tract and the vagina. These bacterial lipids
278 could be tipping factors enhancing autoimmunity in man. In a study by Nichols et al., *P.*
279 *gingivalis* phosphorylated dihydroceramides, particularly PE DHC, significantly increased

280 experimental allergic encephalomyelitis (EAE) in a murine model of multiple sclerosis (35). EAE
281 was used as a model for autoimmune disease in this study. The increased autoimmune disease
282 severity resulting from administration of *P. gingivalis* lipids was mediated in a TLR2-dependent
283 manner. Though the enhanced TLR2-dependent autoimmune response was attributed to PE DHC
284 lipids, other minor lipid classes of *P. gingivalis*, including the recently described serine dipeptide
285 lipids, could account for the enhanced engagement of TLR2.

286

287 **COMPARATIVE EFFECTS OF SPHINGOLIPIDS IN INFLAMMATORY** 288 **DISEASES**

289 The distribution of PDHC lipid classes was different in diseased periodontal tissues compared to
290 tissues from healthy controls (23, 51). The primary dihydroceramide lipids of *P. gingivalis*
291 recovered from diseased gingival tissue were the unsub PG DHC lipids whereas lesser amounts
292 of PE DHC and sub PG DHC lipids were detected. PG DHC lipids were also more abundant than
293 PE DHC lipids on periodontally-diseased teeth (51). This suggested that progression of disease
294 could be associated with a shift in the PDHCs species released from the microbiota associated
295 with periodontitis or a shift in the transport or metabolic hydrolysis of specific PDHC lipids in
296 diseased gingival tissues. PE DHC and PG DHCs also affected gingival fibroblasts differently,
297 probably due to differences in their polar head groups (18). As already mentioned, sub PG DHCs
298 caused fibroblast rounding in culture and increased the production of prostaglandin E₂ with IL-1 β
299 co-treatment (18), and promoted apoptosis in endothelial cells (42) and chondrocytes (39). In
300 contrast, the phosphatidylethanolamine (PEA) lipid fraction did not induce endothelial apoptosis
301 *in vitro* (42) but did promote cell rounding in gingival fibroblasts (24). Because a homologous
302 synthetic PEA lipid standard without *isobranched* fatty acids did not cause cell rounding, it was
303 concluded that the *isobranched* aliphatic chains are also contributing to the apparent cell rounding
304 of gingival fibroblasts (24). The difference in the biological activity of PG DHC and PE DHC
305 has been ascribed to the different phosphorylated head group substitution and/or the addition of
306 esterified *isobranched* C_{15:0} fatty acid (18, 51). The interpretation of the relative clinical
307 importance of dihydroceramides is additionally complicated by the fact that members of other
308 genera in the oral and intestinal microbiota can produce PDHC lipids such as *Bacteroides*,

309 *Parabacteroides*, *Prevotella*, *Tannerella* and *Porphyromonas* (23). However, none of these
310 bacteria, except for *T. forsythia*, are considered keystone pathogens in periodontitis.

311

312 **CONCLUDING REMARKS**

313 Sphingolipids are not only structural components of mammalian membranes but have important
314 functions in specialized membrane domains (lipid rafts and protein complexes) and affect
315 signaling for a number of cellular processes. Bacterial sphingolipids are similar in structure but
316 are not identical to human sphingolipids. The importance of sphingolipids in disease has often
317 been overshadowed by that of LPS, which in the case of *P. gingivalis* LPS can be contaminated
318 with sphingolipids when prepared by published methods. *P. gingivalis* sphingolipids and serine
319 dipeptide lipids produce cellular effects particularly relevant to the essential pathological features
320 of periodontitis including promotion of osteoclastogenesis and inhibition of osteoblast function.
321 *P. gingivalis* sphingolipids also potentiate prostaglandin secretion from gingival fibroblasts and
322 are implicated in promoting IL-6 secretion from dendritic cells. These lipids also promote
323 apoptosis in endothelial cells, potentially contributing to vascular lesions. The latter could be
324 important in cardiovascular disease since *P. gingivalis* PDHC and serine dipeptide lipids have
325 been detected in carotid atherosclerotic lesions. However, *P. gingivalis* is not the only organism
326 responsible for production of dihydroceramide and serine dipeptide lipids since several bacterial
327 species and genera within members of the Bacteroidetes phylum of the oral cavity, vagina and
328 intestine may account for these lipids in blood, tissues and brain. Recovery of PDHC lipids in
329 human brain tissues could occur through transport of PDHC lipids in blood and subsequent
330 deposition into vascular elements of neural tissues, but could also result from penetration through
331 the blood brain barrier. Future research will evaluate these possibilities. *P. gingivalis* is not the
332 sole causal agent in periodontitis either, although it is regarded as the most important keystone
333 bacterium here. Recently discovered serine dipeptide lipids of *P. gingivalis* have been implicated
334 in alveolar bone loss in chronic periodontitis and represent a new class of TLR2 ligands with
335 structural similarity to diacylated lipopeptides. Lipid 430 is highly unusual in that it produces
336 strong proinflammatory responses and inhibitory effects on osteoblasts, and yet it contains only
337 one fatty acid acyl chain. Bacterial sphingolipids might also play a role in autoimmune disease
338 through acute and chronic activation of the immune system e.g., in rheumatoid arthritis and

339 multiple sclerosis. The distribution and composition of DHCs depend on the tissue site and
340 disease status. This implies that healthy periodontal sites may contain bacterial sphingolipids but
341 the distribution can be different from that in diseased sites. Since these bacterial sphingolipids
342 and serine dipeptide lipids are recovered in periodontal and other human tissues and since they
343 possess important biological properties affecting inflammation and host responses, they should be
344 classified as virulence factors. Research on the role of these substances in human diseases, which
345 are only beginning to be understood, should be intensified.

346

347 **ACKNOWLEDGMENTS**

348

349 FCN acknowledges grants from the National Multiple Sclerosis Society and NIH Grant
350 DE021055.

351

352

353 **REFERENCES**

- 354 1. Lingwood D, and Simons K. 2010. Lipid rafts as a membrane-organizing principle.
355 Science 327:46-50.
- 356 2. Nicolson GL. 2014. The fluid-mosaic model of membrane structure: Still relevant to
357 understanding the structure, function and dynamics of biological membranes after more
358 than 40 years. Biochim Biophys Acta 1838:1451-1466.
- 359 3. Heaver SL, Johnson EL, and Ley RE. 2018. Sphingolipids in host-microbial interactions.
360 Curr Opin Microbiol 43:92-99.
- 361 4. Gomi K, Kawasaki K, Kawai Y, Shiozaki M, and Nishijima M. 2002. Toll-like receptor
362 4-md-2 complex mediates the signal transduction induced by flavolipin, an amino acid-
363 containing lipid unique to *Flavobacterium meningosepticum*. J Immunol 168:2939-2943.
- 364 5. Nemati R, Dietz C, Anstadt E, Clark R, Smith M, Nichols F, and Yao X. 2017.
365 Simultaneous determination of absolute configuration and quantity of lipopeptides using
366 chiral liquid chromatography/mass spectrometry and diastereomeric internal standards.
367 Anal Chem 89:3583-3589.
- 368 6. Nemati R, Dietz C, Anstadt EJ, Cervantes J, Liu Y, Dewhirst FE, Clark RB, Finegold S,
369 Gallagher JJ, Smith MB, Yao X, and Nichols FC. 2017. Deposition and hydrolysis of
370 serine dipeptide lipids of bacteroidetes bacteria in human arteries: Relationship to
371 atherosclerosis. J Lipid Res 58:1999-2007.
- 372 7. Shiozaki M, Degucki N, Mochizuki T, Wakabayashi T, Ishikawa T, Haruyama,H, Kawai
373 Y, and Nishijima M. 1998. Revised structure of flavolipin and synthesis of its isomers.
374 Tetrahedron Lett 39:4497-4500.

- 375 8. Wang M, and Hajishengallis G. 2008. Lipid raft-dependent uptake, signalling and
376 intracellular fate of *Porphyromonas gingivalis* in mouse macrophages. *Cell Microbiol*
377 10:2029-2042.
- 378 9. Tsuda K, Amano A, Umebayashi K, Inaba H, Nakagawa I, Nakanishi Y, and Yoshimori
379 T. 2005. Molecular dissection of internalization of *Porphyromonas gingivalis* by cells
380 using fluorescent beads coated with bacterial membrane vesicle. *Cell Struct Funct* 30:81-
381 91.
- 382 10. Tsuda K, Furuta N, Inaba H, Kawai S, Hanada K, Yoshimori T, and Amano A. 2008.
383 Functional analysis of alpha5beta1 integrin and lipid rafts in invasion of epithelial cells by
384 *Porphyromonas gingivalis* using fluorescent beads coated with bacterial membrane
385 vesicles. *Cell Struct Funct* 33:123-132.
- 386 11. Eke PI, Dye BA, Wei L, Slade GD, Thornton-Evans GO, Borgnakke WS, Taylor GW,
387 Page RC, Beck JD, and Genco RJ. 2015. Update on prevalence of periodontitis in adults
388 in the united states: Nhanes 2009 to 2012. *J Periodontol* 86:611-622.
- 389 12. Olsen I. 2015. From the acta prize lecture 2014: The periodontal-systemic connection
390 seen from a microbiological standpoint. *Acta Odontol Scand* 73:563-568.
- 391 13. Olsen I. 2017. Oral microbial dysbiosis precedes development of pancreatic cancer. *J Oral*
392 *Microbiol* 9:1374148.
- 393 14. Olsen I, and Singhrao SK. 2015. Can oral infection be a risk factor for Alzheimer's
394 disease? *J Oral Microbiol* 7:29143.
- 395 15. Nichols FC. 1994. Distribution of 3-hydroxy C_{17:0} in subgingival plaque and gingival
396 tissue samples: Relationship to adult periodontitis. *Infect Immun* 62:3753-3760.
- 397 16. Nichols FC, and Maraj B. 1998. Relationship between hydroxy fatty acids and
398 prostaglandin E₂ in gingival tissue. *Infect. Immun.* 66:5805-5811.

- 399 17. Nichols FC. 1998. Novel ceramides recovered from *Porphyromonas gingivalis*:
400 Relationship to adult periodontitis. J. Lipid Res. 39:2360-2372.
- 401 18. Nichols FC, Riep B, Mun J, Morton MD, Bojarski MT, Dewhirst FE, and Smith MB.
402 2004. Structures and biological activity of phosphorylated dihydroceramides of
403 *Porphyromonas gingivalis*. J Lipid Res 45:2317-2330.
- 404 19. Clark RB, Cervantes JL, Maciejewski MW, Farrokhi V, Nemati R, Yao X, Anstadt E,
405 Fujiwara M, Wright KT, Riddle C, La Vake CJ, Salazar JC, Finegold S, and Nichols FC.
406 2013. Serine lipids of *Porphyromonas gingivalis* are human and mouse toll-like receptor 2
407 ligands. Infect Immun 81:3479-3489.
- 408 20. Nichols FC, Levinbook H, Shnaydman M, and Goldschmidt J. 2001. Prostaglandin E₂
409 secretion from gingival fibroblasts treated with interleukin-1beta: Effects of lipid extracts
410 from *Porphyromonas gingivalis* or calculus. J Periodontal Res 36:142-152.
- 411 21. Saglie FR, Smith CT, Newman MG, Carranza FA, Jr., Pertuiset JH, Cheng L, Auil E, and
412 Nisengard RJ. 1986. The presence of bacteria in the oral epithelium in periodontal
413 disease. I. Immunohistochemical identification of bacteria. J Periodontol 57:492-500.
- 414 22. Sandros J, Papapanou P, and Dahlen G. 1993. *Porphyromonas gingivalis* invades oral
415 epithelial cells in vitro. J Periodontal Res 28:219-226.
- 416 23. Nichols FC, Yao X, Bajrami B, Downes J, Finegold SM, Knee E, Gallagher JJ, Housley
417 WJ, and Clark RB. 2011. Phosphorylated dihydroceramides from common human
418 bacteria are recovered in human tissues. PLoS One 6:e16771.
- 419 24. Nichols FC, Riep B, Mun J, Morton MD, Kawai T, Dewhirst FE, and Smith MB. 2006.
420 Structures and biological activities of novel phosphatidylethanolamine lipids of
421 *Porphyromonas gingivalis*. J Lipid Res 47:844-853.

- 422 25. Wang YH, Nemati R, Anstadt E, Liu Y, Son Y, Zhu Q, Yao X, Clark RB, Rowe DW, and
423 Nichols FC. 2015. Serine dipeptide lipids of *Porphyromonas gingivalis* inhibit osteoblast
424 differentiation: Relationship to toll-like receptor 2. *Bone*.
- 425 26. Triantafilou M, Morath S, Mackie A, Hartung T, and Triantafilou K. 2004. Lateral
426 diffusion of toll-like receptors reveals that they are transiently confined within lipid rafts
427 on the plasma membrane. *J Cell Sci* 117:4007-4014.
- 428 27. Farrokhi V, Nemati R, Nichols FC, Yao X, Anstadt E, Fujiwara M, Grady J, Wakefield D,
429 Castro W, Donaldson J, and Clark RB. 2013. Bacterial lipodipeptide, lipid 654, is a
430 microbiome-associated biomarker for multiple sclerosis. *Clin Transl Immunology* 2:e8.
- 431 28. Olsen I, and Jantzen E. 2001. Sphingolipids in bacteria and fungi. *Anaerobe* 7:103-112.
- 432 29. Kanzaki H, Movila A, Kayal R, Napimoga MH, Egashira K, Dewhirst F, Sasaki H,
433 Howait M, Al-Dharrab A, Mira A, Han X, Taubman MA, Nichols FC, and Kawai T.
434 2017. Phosphoglycerol dihydroceramide, a distinctive ceramide produced by
435 *Porphyromonas gingivalis*, promotes RANKL-induced osteoclastogenesis by acting on
436 non-muscle myosin ii-a (myh9), an osteoclast cell fusion regulatory factor. *Biochim*
437 *Biophys Acta* 1862:452-462.
- 438 30. Wang YH, Jiang J, Zhu Q, Alanezi AZ, Clark RB, Jiang X, Rowe DW, and Nichols FC.
439 2010. *Porphyromonas gingivalis* lipids inhibit osteoblastic differentiation and function.
440 *Infect Immun* 78:3726-3735.
- 441 31. Kalajzic I, Kalajzic Z, Kaliterna M, Gronowicz G, Clark SH, Lichtler AC, and Rowe D.
442 2002. Use of type I collagen green fluorescent protein transgenes to identify
443 subpopulations of cells at different stages of the osteoblast lineage. *J Bone Miner Res*
444 17:15-25.

- 445 32. Gibson FC, 3rd, and Genco CA. 2007. *Porphyromonas gingivalis* mediated periodontal
446 disease and atherosclerosis: Disparate diseases with commonalities in pathogenesis
447 through TLRs. *Curr Pharm Des* 13:3665-3675.
- 448 33. Gibson FC, 3rd, Ukai T, and Genco CA. 2008. Engagement of specific innate immune
449 signaling pathways during *Porphyromonas gingivalis* induced chronic inflammation and
450 atherosclerosis. *Front Biosci* 13:2041-2059.
- 451 34. Papadopoulos G, Weinberg EO, Massari P, Gibson FC, 3rd, Wetzler LM, Morgan EF,
452 and Genco CA. 2013. Macrophage-specific TLR2 signaling mediates pathogen-induced
453 TNF-dependent inflammatory oral bone loss. *J Immunol* 190:1148-1157.
- 454 35. Nichols FC, Housley WJ, O'Connor CA, Manning T, Wu S, and Clark RB. 2009. Unique
455 lipids from a common human bacterium represent a new class of Toll-like receptor 2
456 ligands capable of enhancing autoimmunity. *Am J Pathol* 175:2430-2438.
- 457 36. Mirucki CS, Abedi M, Jiang J, Zhu Q, Wang YH, Safavi KE, Clark RB, and Nichols FC.
458 2014. Biologic activity of *Porphyromonas endodontalis* complex lipids. *J Endod* 40:1342-
459 1348.
- 460 37. Nichols FC, Bajrami B, Clark RB, Housley W, and Yao X. 2012. Free lipid A isolated
461 from *Porphyromonas gingivalis* lipopolysaccharide is contaminated with phosphorylated
462 dihydroceramide lipids: Recovery in diseased dental samples. *Infect Immun* 80:860-874.
- 463 38. Kassem A, Henning P, Lundberg P, Souza PP, Lindholm C, and Lerner UH. 2015.
464 *Porphyromonas gingivalis* stimulates bone resorption by enhancing RANKL (receptor
465 activator of NF-kappaB ligand) through activation of Toll-like receptor 2 in osteoblasts. *J*
466 *Biol Chem* 290:20147-20158.

- 467 39. Zahlten J, Riep B, Nichols FC, Walter C, Schmeck B, Bernimoulin JP, and Hippenstiel S.
468 2007. *Porphyromonas gingivalis* dihydroceramides induce apoptosis in endothelial cells. J
469 Dent Res 86:635-640.
- 470 40. Desta T, and Graves DT. 2007. Fibroblast apoptosis induced by *Porphyromonas*
471 *gingivalis* is stimulated by a gingipain and caspase-independent pathway that involves
472 apoptosis-inducing factor. Cell Microbiol 9:2667-2675.
- 473 41. Rohner E, Detert J, Kolar P, Hocke A, N'Guessan P, Matziolis G, Kanitz V, Bernimoulin
474 JP, Kielbassa A, Burmester GR, Buttgerit F, and Pischon N. 2010. Induced apoptosis of
475 chondrocytes by *Porphyromonas gingivalis* as a possible pathway for cartilage loss in
476 rheumatoid arthritis. Calcif Tissue Int.
- 477 42. Rohner E, Hoff P, Matziolis G, Perka C, Riep B, Nichols FC, Kielbassa AM, Detert J,
478 Burmester GR, Buttgerit F, Zahlten J, and Pischon N. 2012. The impact of
479 *Porphyromonas gingivalis* lipids on apoptosis of primary human chondrocytes. Connect
480 Tissue Res 53:327-333.
- 481 43. de Pablo P, Chapple IL, Buckley CD, and Dietrich T. 2009. Periodontitis in systemic
482 rheumatic diseases. Nat Rev Rheumatol 5:218-224.
- 483 44. de Pablo P, Dietrich T, and McAlindon TE. 2008. Association of periodontal disease and
484 tooth loss with rheumatoid arthritis in the us population. J Rheumatol 35:70-76.
- 485 45. Kaur S, White S, and Bartold PM. 2013. Periodontal disease and rheumatoid arthritis: A
486 systematic review. J Dent Res 92:399-408.
- 487 46. Moye ZD, Valiuskyte K, Dewhirst FE, Nichols FC, and Davey ME. 2016. Synthesis of
488 sphingolipids impacts survival of *Porphyromonas gingivalis* and the presentation of
489 surface polysaccharides. Front Microbiol 7:1919.

- 490 47. Willis LM, Stupak J, Richards MR, Lowary TL, Li J, and Whitfield C. 2013. Conserved
491 glycolipid termini in capsular polysaccharides synthesized by ATP-binding cassette
492 transporter-dependent pathways in Gram-negative pathogens. *Proc Natl Acad Sci U S A*
493 110:7868-7873.
- 494 48. Bainbridge BW, Hirano T, Grieshaber N, and Davey ME. 2015. Deletion of a 77-base-
495 pair inverted repeat element alters the synthesis of surface polysaccharides in
496 *Porphyromonas gingivalis*. *J Bacteriol* 197:1208-1220.
- 497 49. An D, Na C, Bielawski J, Hannun YA, and Kasper DL. 2011. Membrane sphingolipids as
498 essential molecular signals for *Bacteroides* survival in the intestine. *Proc Natl Acad Sci U*
499 *S A* 108 Suppl 1:4666-4671.
- 500 50. Henry LG, McKenzie RM, Robles A, and Fletcher HM. 2012. Oxidative stress resistance
501 in *Porphyromonas gingivalis*. *Future Microbiol* 7:497-512.
- 502 51. Nichols FC, and Rojanasomsith K. 2006. *Porphyromonas gingivalis* lipids and diseased
503 dental tissues. *Oral Microbiol Immunol* 21:84-92.

504

505

506 **FIGURE LEGENDS**

507

508 **FIGURE 1** Model for phosphorylated dihydroceramide and serine dipeptide lipid penetration
509 into gingival tissues and relevant biological effects in the expression of chronic periodontitis. (1)
510 The serine dipeptide parent lipid, Lipid 654, is recovered in subgingival calculus and subgingival
511 plaque. Lipid 654 promotes osteoclast formation from RAW cells, inhibits osteoblast
512 differentiation and function, and is implicated in dendritic cell release of IL-6. (2) Lipid 654 can
513 be de-esterified by mammalian phospholipase A2 (PLA2) enzymes, thus producing within
514 gingival tissues another serine dipeptide lipid, Lipid 430. Lipid 430 inhibition of osteoblast
515 differentiation and function occurs at lower levels when compared with Lipid 654. (3)
516 Phosphorylated dihydroceramide lipids (PDHCs) including PE DHC, sub PG DHC and unsub PG
517 DHC lipids (see **FIGURE 2**), are abundant in lipid extracts of subgingival calculus, but are also
518 recovered in subgingival plaque and gingival tissues. (4) Sub PG DHC lipids promote IL-1 β -
519 mediated prostaglandin production in gingival fibroblasts and cell fusion during
520 osteoclastogenesis of RAW cells. (5) Sub PG DHC lipids promote gingival fibroblast cell death
521 in culture. Penetration of sub PG DHC lipids through junctional epithelium could therefore
522 promote fibroblast cell death along the tooth root surface.


523 **FIGURE 2** Structures of novel *P. gingivalis* dihydroceramide and phospholipids (^a adapted from
524 (18), ^b from (51), ^c from (17) and ^d from (24)). *The long chain bases vary from 17 to 19 carbons
525 in length. The 17 and 19 carbon long chain bases are *isobranched* as shown but the 18 carbon
526 long chain base exists as a straight aliphatic chain. Note the *isobranched* saturated fatty acids
527 (C_{15:0} and C_{13:0}) in phosphatidylethanolamine (PEA) lipids.

528

529 **FIGURE 3** Structures of serine dipeptide lipids from *P. gingivalis* (adapted from (7, 19)). *Lipid
530 654 was originally described in *Flavobacterium meningosepticum* and was termed Flavolipin by
531 Shiozaki et al. (7).
532

533 **FIGURE 1.**

534




ScEYence Studios
ASM Journals
MMBR00035-18
Dr. Nichols
Figure: 01

535

536 **FIGURE 2.**

537




538

539

540 **FIGURE 3.**

541



542

543

544 **TABLE 1** Lipid abbreviations

545

546	DHC	Dihydroceramide
547	PE DHC	Phosphoethanolamine dihydroceramide
548	PG DHC	Phosphoglycerol dihydroceramide
549	PDHCs	Phosphorylated dihydroceramides
550	Sub PG DHC	Substituted phosphoglycerol dihydroceramide
551	Unsub PG DHC	Unsubstituted phosphoglycerol dihydroceramide
552	PEA	Phosphatidylethanolamine

553

554

555

556